Retinal health and nerve markers in MS patients taking ofatumumab
Treatments studied
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This study looks at how ofatumumab (Kesimpta) affects the back of the eye (retina) and certain nerve proteins in the blood in people with relapsing multiple sclerosis. It may help doctors understand how well the medication is protecting the eyes and nerves.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- Your doctor has confirmed you have relapsing multiple sclerosis (RMS).
- You are either about to start ofatumumab (Kesimpta) in the next 60 days, or you are already taking it.
- You are willing to give a blood sample (phlebotomy).
- You do not have uncontrolled diabetes, uncontrolled high blood pressure, glaucoma, severe nearsightedness/farsightedness, or other eye or nerve problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if ofatumumab can help people with relapsing multiple sclerosis (RMS) by measuring its effect on nerve damage markers in the blood. It aims to see if the drug is safe and effective for controlling relapses and slowing disease activity.
This study looks at what happens to infection-fighting antibody levels when people with relapsing multiple sclerosis switch from ocrelizumab to ofatumumab. It may help doctors understand if switching is a good option for people whose antibody levels are low.
This study uses advanced eye imaging (OCTA) and visual field testing to look at how multiple sclerosis affects the retina and optic nerve. The goal is to better understand the disease and potentially help track it.
This study uses advanced eye scans (OCT and retinal vessel imaging) to look for patterns in the retina that might be different in people with Multiple Sclerosis and other neuroinflammatory diseases. The goal is to find markers that could help doctors better understand and monitor these conditions.
This study tests a new treatment that combines a type of immune cell therapy with a targeted antibody to see if it can help people with multiple sclerosis. It aims to reduce the immune system's attack on the nervous system and potentially slow disease progression.
This trial uses a type of eye scan (OCT) to look at the retina in people with brain conditions like multiple sclerosis, Alzheimer's, Parkinson's, or migraines. It aims to see if these scans can help doctors learn more about the disease and monitor it over time.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.